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The bacterial burden on human health is quickly outweighing available therapeutics. Our long-term goal is
the development of antimicrobials with the potential for broad-spectrum activity. We previously reported
phthalazine-based inhibitors of dihydrofolate reductase (DHFR) with potent activity against Bacillus anthracis,
a major component of Project BioShield. The most active molecule, named RAB1, performs well in vitro and,
in a cocrystal structure, was found deep within the active site of B. anthracis DHFR. We have now examined the
activity of RAB1 against a panel of bacteria relevant to human health and found broad-spectrum applicability,
particularly with regard to Gram-positive organisms. RAB1 was most effective against Staphylococcus aureus,
including methicillin- and vancomycin-resistant (MRSA/VRSA) strains. We have determined the cocrystal
structure of the wild-type and trimethoprim-resistant (Phe 98 Tyr) DHFR enzyme from S. aureus with RAB1,
and we found that rotational freedom of the acryloyl linker region allows the phthalazine moiety to occupy two
conformations. This freedom in placement also allows either enantiomer of RAB1 to bind to S. aureus, in
contrast to the specificity of B. anthracis for the S-enantiomer. Additionally, one of the conformations of RAB1
defines a unique surface cavity that increases the strength of interaction with S. aureus. These observations
provide insights into the binding capacity of S. aureus DHFR and highlight atypical features critical for future
exploitation in drug development.
Despite the introduction of antibiotics such as penicillin in
the 1940s and approval of new classes, such as cyclic li-
popeptides like daptomycin, infectious disease continues
worldwide. Antibiotic resistance is increasing, and reliance
on existing scaffolds is not sufficient to combat multidrug
resistance (23, 33). Staphylococcus aureus has become a pri-
mary concern among antibiotic-resistant infectious disease
agents, with methicillin-resistant S. aureus (MRSA) infec-
tions claiming 19,000 lives in the United States per year and
costing the United States $3 to 4 billion dollars per year
(18). As the incidence of MRSA has shifted from hospital
settings to the community at large, treatment preferences
have moved to oral formulations and have impacted drug
resistance profiles. Community-acquired MRSA is showing
increasing resistance to fluoroquinolones and clindamycin,
and in response clinicians are shifting to doxycycline, lin-
ezolid, or trimethoprim-sulfamethoxazole as the best op-
tions for outpatient treatment (21, 30).
While treatment preferences are adjusting to isolated out-
breaks, S. aureus is increasingly resistant to trimethoprim
(TMP) (13). TMP targets the enzyme dihydrofolate reductase
(DHFR), a critical component of folate metabolism, and is
required for continued nucleic acid synthesis (6). DHFR is a
good target because of the specificity that can be achieved;
however, bacteria have developed resistance mechanisms that
include acquisition of plasmid-derived (though catalytically in-
ferior) versions of DHFR, leading to high-level resistance.
Alternatively, point mutations of the chromosomal DHFR
have been demonstrated to confer intermediate resistance,
such as the S. aureus DHFR (saDHFR) residue Phe 98 to Tyr
(F98Y) mutation (13). While other mutations are frequently
found with F98Y, it alone can increase the MIC of TMP by at
least 1 order of magnitude. In efforts to compensate for a lower
inhibitory action, TMP is frequently combined with a sulfa
inhibitor of the enzyme preceding DHFR, termed dihydrop-
terin synthase (DHPS). Unfortunately, sulfa drugs have noto-
riously poor pharmacokinetics and can have unpleasant, and
sometimes fatal, side effects (15).
RAB1 is a lead compound under investigation for treatment
of inhalation anthrax. RAB1’s structure is modeled on tri-
methoprim but is extended by addition of an acryloyl linker
and phthalazine moiety, including a propyl group at a stereo-
genic carbon. This results in approximately 40% more surface
area than TMP, which provides critical contact regions for
further interaction with the binding site. Specific structural
features of RAB1 allow unique contacts with the protein that
can overcome natural and induced resistance. For B. anthracis,
the half-maximal inhibitory concentration (IC50) of purified
DHFR enzyme with TMP is 77 M, indicating a natural resis-
tance, while with RAB1 it is 60 nM (3). Selectivity for the
binding site in B. anthracis DHFR is controlled by the large
hydrophobic phthalazine moiety, which is embedded within
and causes extension of the binding site (4). Concomitant with
the current work, the broad-spectrum activities of related
RAB1-like molecules have been demonstrated by Basilea
Pharmaceutica International AG. These studies also high-
lighted the difficulty in generating spontaneous resistant mu-
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tations of chromosomal DHFR to inhibitors in the dihydroph-
thalazine series (7, 9).
We have characterized the broad-spectrum applicability of
RAB1 and its particular effectiveness against S. aureus, includ-
ing MRSA and vancomycin-resistant S. aureus (VRSA) strains.
Both enantiomers of RAB1 show potent antimicrobial activi-
ties, as indicated by favorable MICs and IC50s. The impact of
the TMP resistance-conferring mutation F98Y is negligible on
RAB1 activity and preferentially decreases binding of the R-
enantiomer. The X-ray crystal structures of RAB1 complexed
to S. aureus DHFR reveal two conformations for the large
phthalazine group. While one conformation resides in the
known binding site, the other sits in a shallow surface cavity
that has been previously undocumented as susceptible to in-
hibitor binding. This allows an increase in binding strength and
provides an explanation for the lack of enantiomeric prefer-
ence. These observations provide insights into the binding ca-
pacity of S. aureus DHFR and highlight atypical features crit-
ical for future exploitation in drug development, as well as
insights into the mechanism of action of phthalazine-based
inhibitors.
MATERIALS AND METHODS
Synthesis of RAB1 and purification of its component enantiomers have been
previously described (4, 5).
Determination of the MIC. The MIC determination experiments were carried
out through the NIH/NIAID In vitro Assessment for Antimicrobial Activity
Resource for Researchers program. Bacterial strains were obtained through the
Biodefense and Emerging Infectious Research Repository, NIAID, NIH, or
from the American Type Culture Collection. Experiments with Bacillus anthracis
Ames, Brucella abortus 2308, Francisella tularensis Schu4, and Yersinia pestis
CO92 were carried out in a CDC-registered and approved biosafety level 3
(BSL-3) laboratory with appropriate biosafety and security measures. Experi-
ments with other organisms/strains were carried out in a BSL-2 laboratory with
appropriate biosafety and security measures. The MICs were determined using
a broth microdilution assay in accordance with the Clinical and Laboratory
Standards Institute (CLSI) recommendations (10). Each MIC was determined in
duplicate for two replicates; 96-well plates containing 2-fold serial dilutions of
test compounds or commercial antibiotics (used for quality control as directed by
CLSI guidelines [11]) were prepared in cation-adjusted Mueller-Hinton broth
for all agents (with the addition of 2% IsoVitaleX for F. tularensis), except B.
abortus, which was grown in Brucella broth. Ten microliters of a standardized
inoculum was used to infect wells containing 100 l of medium with or without
drug. Inoculum concentrations were verified by plating for CFU using the CLSI
recommended protocol (10). Experimental controls included growth control
wells, sterility control wells, and uninoculated drug wells to verify that test
compounds remained soluble under experimental conditions. Antimicrobial sus-
ceptibility testing was performed for single isolates under the following condi-
tions: B. anthracis for 16 h, Y. pestis for 24 h, B. abortus for 48 h, F. tularensis for
48 h with 5% CO2, and vancomycin-resistant enterococci (VRE) for 20 h, all at
37°C. Four MRSA strains were grown for 18 h, and three VRSA strains were
grown for 20 h, all at 35°C. After the appropriate incubation, plates were allowed
to equilibrate to room temperature for 30 min. They were then sealed, and the
absorbance at 600 nm was spectrophotometrically measured to determine the
MIC, defined as the lowest compound concentration that inhibited growth of
the microorganism. Visual confirmation of growth was also performed. When
variation was obtained in experimental values the MIC is reported as a range.
Growth patterns with some S. aureus strains exhibited trailing, as has been
previously noted for folate pathway inhibitors (10). In these instances, MIC
values were calculated as the concentration of compound resulting in an 80%
reduction in growth of the microorganism. However, this did not result in a shift
of a MIC from that obtained using the lowest concentration of compound that
inhibited growth of the microorganism.
Antibiotic susceptibility profiles for S. aureus isolates were obtained from the
Network on Antimicrobial Resistance in Staphylococcus aureus website and are
listed in Table 1.
Enzyme activity and calculation of the IC50. Purified recombinant wild-type
(wt) and F98Y S. aureus DHFR proteins were stored at 80°C in 10% glycerol
(see the description of protein production and purification methods, below); the
presence of the histidine tag did not affect activity. The assay was adapted from
the standard format (2) to a high-throughput 96-well plate platform with a 200-l
total reaction volume and was carried out with a Biomek 2000 liquid handling
robot interfaced with a DTX880 plate reader. Enzyme, saturating NADPH, and
inhibitor in dimethyl sulfoxide were preincubated at 30°C; the reaction was
initiated by the addition of dihydrofolic acid (DHF) and monitored for 3 min,
during which time the reaction remained linear. The protein concentration (4.5
nM) was adjusted to yield an activity of 1.4 nmol DHF reduced per minute for
the wild-type DHFR. Detection utilized the redox-sensitive tetrazolium dye
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS). MTS is reduced by the product tetrahydrofolate to yield an
increased absorbance at 450 nm, in contrast to the standard assay, which follows
the loss of cofactor (oxidation of NADPH) at 340 nm. The increasing signal from
MTS reduction is greater than the loss of signal upon NADPH oxidation, facil-
itating measurement of smaller volumes using shorter path lengths. Reactions
were performed in triplicate. The change in signal was calculated as a percentage
of a reaction with no inhibitor over 2.8 min of reaction and was used to calculate
an absolute IC50 from the fit of a four-parameter logistic model using the KC Jr.
plate reader software. The Michaelis-Menten constants (Km) for the DHF sub-
strate were calculated by fitting the Michaelis-Menten equation in Microsoft
Excel using the solver plug-in. The IC50 and Km values were used to compute the
equilibrium inhibition constant (Ki) by using the formalism of Cheng-Prusoff (8).
TABLE 1. Antibiotic susceptibility profiles for S. aureus isolatesa
Drugb
MIC (g/ml)/CLSI interpretationc
NRS1 NRS70 NRS71 NRS123 VRS1 VRS2 VRS3
VAN 8/I 0.5/S 0.5/S 1/S 256/R 64/R 32/R
TEC 8/S 0.25/S 0.5/S 1/S 64/R 8/S 16/I
CIP 16/R 0.5/S 16/R 0.5/S 16/R 16/R 16/R
DAP 2/NA 0.5/NA
CLI 4/R 4/R 0.12/S 4/R 4/R 4/R
ERY 8/R 8/R 0.5/S 8/R 8/R 8/R
GEN 16/R 1/S 0.5/S 0.5/S 16/R 16/R 16/R
LNZ 1/S 1/S 2/S 2/S 1/S 2/S
OXA 32/R 16/R 16/R 16/R 16/R 16/R 16/R
PEN 8/R 2/R 2/R 2/R 2/R 2/R 2/R
SYN 0.12/S 0.5/S 1/S 0.25/S 0.5/S 0.5/S 0.5/S
TET 32/R 32/R
SXT 0.12/2.28/S 0.25/4.75/S 0.25/4.75/S 0.25/4.75/S 2/38/S 1/19/S 0.25/4.75/S
a Data taken from www.narsa.net.
b Abbreviations of drugs: VAN, vancomycin; TEC, teicoplanin; CIP, ciprofloxacin; CLI, clindamycin; ERY, erythromycin; GEN, gentamicin; LNZ, linezolid; OXA,
oxacillin; PEN, penicillin; SYN, quinupristin-dalfopristin; TET, tetracycline; SXT, trimethoprim-sulfamethoxazole.
c S, susceptible; R, resistant; I, intermediate; NA, not available.
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The Ki value allows for direct comparison between the wild-type DHFR protein
and the less catalytically active F98Y mutant. Values for Km of DHF were 43.7
5.9 M for wild-type saDHFR and 11.0  1.7 M for the F98Y mutant. These
values reflect differences arising from experimental modification, but trends are
consistent with previously published values of 5.1 to 14.5 M for the wild-type
enzyme and 0.86 to 7.3 M for the F98Y mutant (13, 14, 20, 26).
Protein production, purification, and crystallization. Recombinant S. aureus
DHFR was expressed from a pET 101D vector (Invitrogen) containing a C-
terminal 6His affinity tag. The F98Y point mutant was generated using the
QuikChange II site-directed mutagenesis kit (Stratagene). Purification utilized
immobilized metal ion affinity chromatography (GE Life Sciences), followed by
cleavage of the affinity tag using an engineered thrombin site. The final step used
an S100 size exclusion column (GE Life Sciences) and exchanged the buffer to 20
mM Tris (pH 8), 150 mM NaCl, and 5% glycerol. Crystallization was carried out
in a hanging drop format at room temperature. Protein was concentrated to 10
to 12 mg/ml and incubated with 1 mM NADPH (Sigma) and a 10-fold molar
excess of RAB1 for at least 2 h prior to initiation of crystallization. The crystal-
lization well contained 15% polyethylene glycol 6000, 0.15 M sodium acetate,
and 0.1 M morpholineethanesulfonic acid (pH 6.5); 2 l of this solution was
mixed with 3 l of protein solution and sealed over the well. Crystals appeared
within a few days and grew to maximum size in 1 to 2 weeks.
X-ray data collection, processing, and refinement. A single crystal was used for
each data collection after cryoprotection in mother liquor with 15% glycerol and
plunging into liquid nitrogen. Data were collected with a Rigaku RU3HR rotat-
ing anode generator coupled with an Raxis 4 image plate detector; data were
indexed with Mosflm (24), scaled with Scala (17), phased by molecular replace-
ment with Phaser (25), and analyzed with PHENIX (1). Refinement was carried
out with Phenix and included a protocol for TLS parameterization with three
groups defined per molecule (28) and was alternated with real-space refinement
and visualization using COOT (16). The initiating methionine residue was not
visible and, following the convention for saDHFR, the next residue (Thr) was
numbered as residue 1. In both structures, residues 71 (Glu), 143 (Glu), and 144
(Lys) had poor side chain density and were refined as alanine residues. Four
additional C-terminal residues resulted from affinity tag cleavage, are visible in
the structures, and make intimate crystal packing contacts. The structures of the
wild type and the F98Y point mutant were completed in space group P6122 with
one molecule per asymmetric unit. The wild-type structure was refined to an R
value of 17.5% (21.3% Rfree), while the F98Y mutant was refined to an R value
of 17.0% (20.7% Rfree); crystallographic statistics are listed in Table 2. Ligand
binding, including buried surface area, was analyzed with the LPC server (32).
Molecular graphics images were produced using the UCSF Chimera package
(29).
Protein Data Bank accession numbers. Coordinates and structure factors have
been deposited with the Protein Data Bank and given accession codes 3M08 for
the ternary complex with wild-type DHFR and 3M09 for the ternary complex
with the F98Y mutant.
RESULTS
Broad-spectrum activity of RAB1. The MIC of RAB1 was
assessed in a broth microdilution assay against a panel of
pathogens relevant to human health. RAB1 inhibited growth
of both Gram-negative (F. tularensis, Y. pestis, and B. abortus)
and Gram-positive (B. anthracis, VRE, and S. aureus) organ-
isms, indicating a broad-spectrum profile of activity (Table 3).
Despite initial selection of RAB1 (previously BAL17662) for
its inhibitory activity against B. anthracis, the present results
demonstrate a potent antistaphylococcal profile (3). Among
the organisms tested, F. tularensis, B. abortus, B. anthracis,
VRS1, and VRS2 have an MIC for TMP of 16 g/ml, which
is classified as resistant by CLSI (11). B. anthracis is naturally
resistant to TMP, while VRS1 and VRS2 contain a plasmid-
encoded TMP-resistant DHFR. Application of the same inter-
pretative standard to MICs with RAB1 would yield only B.
abortus as resistant among this panel. The inhibition of plas-
mid-derived DHFR by RAB1 in the VRSA strains is particu-
larly promising, as TMP is not capable of inhibiting the plas-
mid-derived DHFR enzymes.
Both enantiomers of RAB1 are active. RAB1 is more potent
than TMP for inhibiting growth of wild-type S. aureus. This is
reflected in a reduced IC50 and a decrease of an order of
magnitude in the MIC (Tables 3 and 4). While the F98Y
mutation causes a loss in potency of approximately 10-fold for
TMP, it has a minimal effect on RAB1 binding (Ki of 2.8 nM
versus 0.9 nM for F98Y) (Table 4). Both enantiomers of RAB1
are inhibitory, although the S-enantiomer is more active, as
evidenced by a lower IC50 (2.9 nM for wild-type protein versus
11.5 nM for the R-enantiomer) and a much lower MIC
(0.0625 g/ml for the wild-type strain versus 1 to 1.6 g/ml
with the R-enantiomer). Interestingly, RAB1 activity seems
TABLE 2. Crystallographic data for S. aureus DHFRa
Evaluation phase
and parameter
Value for ternary complex with RAB1,
NADPH, and:
Wild-type DHFR F98Y mutant DHFR
Data collection
Space group P6122 P6122
Cell dimensions
a  b, c (Å) 79.2, 107.9 79.2, 107.9
Resolution (Å) 42.4–2.01 (2.12–2.01) 42.4–2.01 (2.12–2.01)
Rsym 0.037 (0.118) 0.093 (0.403)
I / 23.7 (10.9) 18.9 (7.1)
Completeness (%) 99.6 (98.2) 100.0 (100.0)
Redundancy 5.1 (5.1) 7.3 (7.2)
Refinement
Resolution (Å) 31.9–2.01 39.6–2.01
No. of reflections 13,579 13,953
Rwork/Rfree 0.175/0.213 0.170/0.207
No. of atoms
Protein 1,296 1,296
Ligand/ion 104 104
Water 171 166
B-factors (Å2)
Protein 19.0 19.3
Ligands 16.2 (RAB1) 27.0 (RAB1)
17.0 (NADPH) 15.2 (NADPH)
Water 32.2 31.4
RMS deviations
Bond lengths (Å) 0.005 0.005
Bond angles (°) 1.034 1.018
a Values in parentheses are for the highest-resolution shell. RMS, root mean
square.
TABLE 3. RAB1 has broad-spectrum activity
Strain
MIC (g/ml)
(S,R)-RAB1 TMPa
F. tularensis Schu4 1–2 16
Y. pestis CO92 4–8 1
B. abortus 2308 16 32
B. anthracis Ames 1–4 256
VRE ATCC 700802 0.03 1
MRSA NRS1 0.0625–0.125 2
MRSA NRS70 0.0625–0.25 2–4
MRSA NRS71 0.0625–0.125 2
MRSA NRS123 0.0625–0.25 2
VRSA VRS1 8 256
VRSA VRS2 4 256
VRSA VRS3 0.125 2
a The CLSI interpretive standard for TMP is susceptibility at an MIC of 8
g/ml and resistance at an MIC of 16 g/ml.
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modestly enhanced by the F98Y mutation for the S-enanti-
omer but further decreases the affinity for the R-enantiomer.
While the activity of the racemic mixture is favorable, purifi-
cation of the S-enantiomer yields a superior antimicrobial pro-
file and enhanced activity with the F98Y mutation. It should be
noted that the S-enantiomer performs an order of magnitude
better with the F98Y mutant (Ki of 0.2 nM) than TMP does
with the wild-type protein (Ki of 4.4 nM).
Description of the RAB1 binding site in S. aureus DHFR.
Cocrystallization of saDHFR with RAB1 revealed two confor-
mations for the inhibitor in the binding site irrespective of the
identity of the residue at position 98 (Fig. 1). These two con-
formations of RAB1 are equally populated in the wild-type and
F98Y mutant enzyme. In both structures, the regions of RAB1
most similar to other inhibitors, such as TMP, are bound in a
single position; the two conformations arise from rotational
freedom around the acryloyl linker. This rotation places the
phthalazine moiety either embedded within a hydrophobic
pocket used to bind the substrate or along a surface cavity. The
presence of this secondary binding cavity is a unique observa-
tion among saDHFR inhibitor structures and illustrates a new
area for future development of inhibitors.
The more conserved areas of RAB1 were bound to the
binding site using interactions observed with most inhibitors, as
illustrated in Fig. 1. The diaminopyrimidine (DAP) ring is
embedded within the site and anchored by hydrogen bonds to
residues Leu 5, Val 6, Asp 27, Phe 92, and Thr 111. In addition,
hydrophobic contacts are mediated by residue Ala 7 and the
cofactor NADPH. The consequence of the F98Y mutation
appears to be introduced at the main chain carbonyl of Phe 92,
causing a small shift (0.3 Å) of the nicotinamide ring of the
NADPH cofactor and translating to the DAP ring positioning
of both RAB1 conformations (Fig. 1D). The central aromatic
ring of RAB1 contains two dimethoxy substituents and is slot-
ted into a hydrophobic groove comprised of residues Glu 19,
Leu 20, and Leu 28 on one side and Thr 46 and Phe 92 on the
other. The aromatic portion is oriented parallel with this
groove, and the polar methoxy groups protrude along the top
of the binding site. A long hydrogen bond (3.7 Å) is formed
between the side chain oxygen of Ser 49 and one of the me-
thoxy moieties (Fig. 1A).
For discussion purposes the conformation of RAB1 that
occupies the substrate binding site will be referred to as form
1, while the conformation that reveals the secondary surface
cavity will be termed form 2 (Fig. 1). Form 1 is positioned
along the same path as was previously observed for RAB1
binding to DHFR from B. anthracis (4). This fills a major
pocket lined with residues Val 31, Leu 54, Pro 55, and the
carbon atoms from the side chains of Lys 29, Lys 32, and Arg
57. Residue Asn 56 demarcates the edge of the pocket, but it
is over 5 Å away from RAB1. All contacts between the phthala-
zine moiety and the protein are hydrophobic. The enantio-
meric preference for the propyl group in this conformation is
the same as previously observed, with the S-enantiomer ap-
pearing to be the only occupant (4). While the propyl tail is not
in direct contact with protein atoms, its path follows that of
residue Lys 29. Form 2 utilizes a surface cavity that appears
unique to saDHFR. Residues lining this cavity are Leu 54 and
Pro 55 on one side with Ile 50 and Lys 52 on the opposing side.
This cavity is relatively exposed and results in almost 100 Å2
less buried surface (form 1 buries 680 Å2 while form 2 buries
585 Å2 of the 775 Å2 available). This increase in solvent
exposure is largely limited to the phthalazine moiety and is
highest at the stereogenic carbon (Fig. 1B). The electron den-
sity for the propyl group at the stereogenic carbon is absent for
form 2, indicating that either enantiomer could occupy this
secondary site. It is likely that this secondary site is the key to
the increased affinity for RAB1 with saDHFR versus other
bacterial DHFR enzymes.
For form 1, the phthalazine group is not as buried in
saDHFR as was seen with baDHFR, and no major side chain
movements are noted in saDHFR as a consequence of RAB1
binding. Residue identities between the binding site of
baDHFR and saDHFR are largely conserved, and of the con-
tacting residues in saDHFR five have conservative changes
relative to baDHFR (Leu5Met, Gln19Asn, Asp27Gln,
Lys29Gln, and Ser49Ala). However, the shape of the site in
saDHFR is somewhat more shallow but considerably wider
than baDFHR. Outward movement occurs on each side of the
binding site and is seen in structures with or without NADPH,
indicating this larger shape is intrinsic to saDHFR. On the side
comprised of residues 20 to 25 and helix 1 (residues 26 to 37),
the protein lacks a critical “aromatic sandwich” interaction
between residues His 30 and Phe 151 (Fig. 1C). This unusual
ring stacking is observed in all other DHFR enzymes, as first
reported for Pneumocystis jirovecii DHFR residues Tyr 35 and
Phe 199 (for examples, see Protein Data Bank [PDB] codes
2FZH and 2FZI) and for murine DHFR residues Tyr 33 and
Phe 179 (see PDB code 2FZJ) (12). This interaction is also
present in baDHFR (residues Tyr 31 and Tyr 155) and human
DHFR (Tyr 33 and Phe 179). The face stacking of two aro-
matic rings effectively tethers the orientation of helix 1 of the
active site to the stabilizing 	-sheet of the protein’s core; loss
of this appears to allow more flexibility in the positioning of
helix 1 at one side of the active site. The opposite side of the
binding site is made up by helix 2 (residues 44 to 51) and a loop
TABLE 4. Both enantiomers of RAB1 possess favorable inhibition profiles
TMP
enantiomer
IC50 (Ki)a
wt (Phe 98) TMPr (Tyr98) Activity ratio(Y98/F98)
TMP 14.4  3.6 (4.4  1.1) 539.7 101.1 (53.6 10.0) 37.5 (12.3)
(S,R)-RAB1 9.4 3.9 (2.8  1.2) 8.8  0.9 (0.9  0.03) 0.9 (0.3)
S-RAB1 2.9  0.1 (0.9  0.03) 1.8 0.3 (0.2  0.03) 0.6 (0.2)
R-RAB1 11.5  2.3 (3.5  0.7) 65.4 3.3 (6.5  0.3) 5.7 (1.9)
a Values expressed in nM.
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region (residues 52 to 56). There appear to be fewer stabilizing
interactions for this area, but of note are two Tyr-to-Phe
changes in saDHFR at residues 47 and 68 relative to other
DHFR enzymes (Fig. 1C). In baDHFR, the polar hydroxyl
group of these Tyr residues influences the surrounding regions,
including a hydrogen bond to the main chain of Pro 54 (Pro 55
in saDHFR). The combination of these effects results in a
wider, perhaps more mobile active site architecture, which in
FIG. 1. RAB1 is found in two conformations in the S. aureus DHFR binding site, which is not affected by the trimethoprim-resistant F98Y
mutation. (A) Two-dimensional map of the wild-type S. aureus binding site containing RAB1. Residues are labeled by a single-letter abbreviation
and residue number. Red hatched semicircles denote hydrophobic interactions; hydrogen bonds are indicated by green dashed lines, and the
corresponding distances are listed. The conformations of RAB1 are listed as form 1 and form 2, as discussed in the text. RAB1 enantiomers are
shown; for form 2 either enantiomer can occupy the site, and the orientation of the propyl group was not defined in the crystallographic data.
(B) RAB1 form 2 occupies a unique shallow surface cavity, while form 1 is found embedded in the conventional binding site. (C) View of the
saDHFR enzyme with secondary structure representation and the two sides of the active site colored blue. Residues important to the overall
structure of the binding site are indicated, as discussed in the text. Note that either RAB1 enantiomer can bind in the form 2 conformation. (D) The
F98Y mutation has minimal effects on the structure of saDHFR which are limited to movement of the main chain carbonyl of Phe 92 and 0.3
Å movement of the nicotinamide ring of NADPH and the DAP ring of RAB1. (E) RAB1 will not fit into the human DHFR binding site due to
steric restrictions imposed by a smaller volume, which is contoured in red. Residues with direct clashes to RAB1 are labeled. Coordinates were
obtained from PDB ID 2W3A (Leung et al., unpublished).
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turn allows RAB1 to bind in both the active site (form 1) and
the shallow side cavity (form 2). The saDHFR enzyme has a
unique capacity for inhibitor binding, and RAB1 fully utilizes
this additional flexibility and extra binding surface to yield a
very strong interaction.
Superposition of S. aureus DHFR substrate and inhibitors.
The binding of RAB1 closely mimics that of the natural sub-
strate, DHF (Fig. 2C). The paths of DHF and RAB1 form 1
are essentially identical, and the DAP ring of RAB1 superim-
poses well with the pterin ring of DHF. RAB1’s linker overlays
with the peptide-like linker of DHF, and the end of the para-
aminobenzyl glutamate tail of DHF closely matches the dihy-
dropyridazine portion of the dihydrophthalazine moiety of
RAB1. Finally, the propyl group for the S-enantiomer of
RAB1, as seen in form 1, matches the space used by the
glutamate-like extension on DHF. Additional surfaces are oc-
cupied by RAB1 and include the end of the large hydrophobic
pocket used in accommodating form 1 and the shallow surface
pocket occupied by form 2. The large overlap of the DHF
functionally required binding surface and of RAB1 lessens the
likelihood of resistance mutations arising.
Other cocrystal structures have recently been determined
with saDHFR and inhibitors, including TMP (22), Iclaprim
(26, 27), and a series of propargyl-containing molecules (19,
20). Like RAB1, each of these molecules contains a DAP ring
which docks essentially identically in the protein binding site.
TMP then contains a trimethoxybenzyl ring surrounded by
residues Leu 20, Leu 28, Ile 50, Leu 54, and Phe 92 and the
NADPH cofactor, which superimposes with RAB1’s dime-
thoxybenzyl ring (Fig. 2D) and Iclaprim’s dimethoxychromene
moiety (Fig. 2E). Iclaprim extends from the chromene with a
cyclopropyl ring, creating a chiral carbon with equally active
isomers. The positions occupied by the two conformations of
RAB1’s acryloyl linker region superpose markedly well with
the enantiomeric cyclopropyl groups of Iclaprim, and these
regions all make similar hydrophobic contacts with protein
residues Leu 28, Ile 50, and Leu 54.
RAB1 continues along the binding site and fills the length of
available space as well as the additional surface cavity. The
propargyl-containing molecules present limited similarity to
RAB1 beyond the DAP moiety (Fig. 2F). The propargyl-con-
taining molecules do occupy the same main pocket and make
similar hydrophobic interactions which terminate at a position
equivalent with the linker of RAB1. The most notable features
are found in the inhibitors from PDB ID 3F0Q (unpublished)
and 3F0B (19), which protrude into a space below the surface
cavity occupied by RAB1 in form 2. This is the only other
example of utilization of a secondary binding space, although
with the propargyl inhibitors the space is continuous with the
large hydrophobic pocket.
The positional agreement of these inhibitors and the natural
substrate DHF all reflect a high degree of specificity for the
enzyme. It is speculated that Iclaprim’s equally active isomers
would further reduce resistance mutations from occurring
(26); the extended nature and larger footprint of RAB1 should
heighten this effect. Further, the utilization of a functionally
required area in concert with a secondary binding site provides
limited opportunity for protein mutations conferring resis-
tance.
Steric hindrance accounts for the bacterial specificity of
RAB1. RAB1 is a very poor inhibitor of human DHFR
(hDHFR; IC50, 110 M) and is at least 4 orders of magnitude
more selective for bacterial DHFR (3). The lack of binding to
hDHFR was rationalized by using a superimposition of the
saDHFR-RAB1 structure with hDHFR (PDB ID 2W3A)
(A. K. W. Leung, L. J. Ross, S. Zywno-Van Ginkel, R. C.
Reynolds, L. E. Seitz, V. Pathak, W. W. Barrow, E. L. White,
W. J. Suling, J. R. Piper, and D. W. Borhani, unpublished
data). This revealed an obvious lack of space in the hDHFR
site with severe steric clashes of RAB1 and hDHFR residues
Phe 31, Phe 34, Gln 35, Leu 67, and Arg 70 (Fig. 1E). As
expected, the secondary binding site is not present in hDHFR
and is occluded by loop residues 61 to 64 (Pro, Glu, Lys, and
Asn). Overall, the hDHFR binding site has approximately the
same volume as saDHFR (each 1,290 Å3), but in hDHFR
this volume is a different shape that does not extend down the
length of the binding site as far as saDHFR and bacterial
DHFR enzymes in general. This indicates that the dihydroph-
thalazine moiety confers bacterial specificity to this class of
inhibitors due to steric restrictions with the hDHFR enzyme.
The structure of RAB1 seems to fill the binding site of bacte-
rial DHFR with limiting flexibility and polar interactions (en-
tropic costs) to present an ideal inhibitor for bacterial enzymes.
However, flexibility in the linker region is crucial for accessing
the secondary binding site, which in turn confers the potent
inhibition observed with S. aureus strains.
DISCUSSION
RAB1 is able to inhibit the growth of both Gram-positive
and Gram-negative organisms. With all microorganisms tested,
except Y. pestis, it was more effective than TMP, enabling it to
be developed for broad-spectrum treatment of bacterial infec-
tions. The activity of RAB1 arises from its ability to inhibit the
DHFR enzyme. The binding site of saDHFR possesses unique
properties, including the shallow surface cavity, likely arising
from a lack of stabilizing interactions seen in other DHFR
enzymes (such as the “aromatic sandwich”). An intrinsic prop-
erty of the saDHFR binding site is the ability to accommodate
larger ligands, to the extent that multiple inhibitors have been
observed in more than one conformation. Visualization of
RAB1 binding in the cocrystal structures highlights two possi-
ble conformations for the specificity-conferring phthalazine
group. While one of these was expected, the second confor-
mation delineates a previously unappreciated shallow surface
cavity believed unique to saDHFR. While the expected con-
formation only accommodates the S-enantiomer, as previously
observed with baDHFR, the second conformation appears oc-
cupied by either enantiomer. This limited binding mode for the
R-enantiomer is consistent with higher IC50s (Table 4 and Fig.
2A). The two conformations of RAB1 allow more variability in
the binding mode and account for the increased activity with S.
aureus.
The impact of the F98Y mutation was evidenced by a
marked decrease in activity of TMP but had essentially no
effect on the activity of RAB1. This is in stark contrast to other
inhibitors, including Iclaprim, which has an increase in the IC50
from 2.2 nM to 27 nM when the F98Y mutation is present (Fig.
2E) (27). Surprisingly, the F98Y mutation seems to enhance
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FIG. 2. RAB1 occupies a similar space as the natural substrate and other inhibitors; in addition it utilizes a unique surface cavity. The IC50 of RAB1
is not affected by the F98Y mutation to the same extent as other inhibitors. RAB1 is depicted as yellow in the binding site (blue), residue 98 is marked
with a red surface, and the listed small molecules are superimposed. (A) RAB1 with IC50 data from the current study. (B) BAL0030543, a related
compound under development against S. aureus, with IC50 data from reference 7. (C) Dihydrofolic acid, with coordinates obtained from PDB ID 3FRD
(26) (D) Trimethoprim, with IC50 data from the current study and the coordinates obtained from PDB ID 2W9G with NADPH (22). (E) Iclaprim, with
IC50 and coordinates obtained from PDB IDs 3FYV and 3FYW (27). (F) Propargyl-based inhibitors, with IC50 data and coordinates obtained from PDB
ID 3F0B (19) and from PDB ID 3F0Q (K. M. Frey et al., unpublished; no IC50 data are publicly available).
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binding of the S-enantiomer of RAB1 (IC50 from 2.9 nM to 1.8
nM and Ki from 0.9 nM to 0.2 nM) while concomitantly de-
creasing the activity of the R-enantiomer (IC50 from 11.5 nM
to 65.4 nM and Ki from 3.5 nM to 6.5 nM) (Fig. 2A). The
structural consequence of this is not clear, but the larger size of
RAB1 could attenuate the impact of the F98Y mutation by
allowing less lateral freedom of movement within the site.
Presumably the stress on Phe 92 induced by the mutation (Fig.
1D) must impair binding of form 2 in the surface cavity while
enhancing the interaction with form 1.
There was no evidence for NADPH mobility, as was previ-
ously observed with propargyl-containing inhibitors (19).
These inhibitors were also more sensitive to the F98Y substi-
tutions; both observations are probably related to modifica-
tions to the DAP ring in the propargyl inhibitor series (Fig.
2F). While two members of the biphenyl class of propargyl
inhibitors are demonstrated to occupy a space below the sur-
face cavity identified here, this propargyl inhibitor series lacks
selectivity for bacterial enzymes and possesses IC50 (or Ki)
values an order of magnitude larger than RAB1. Their con-
clusions correctly surmise that extension further into the
DHFR site would provide increased affinity and specificity, as
is demonstrated by RAB1.
The binding of RAB1 is similar to that of Iclaprim. While
the IC50 of RAB1 is greater than that of Iclaprim (14.4 nM
versus 2.2 to 7 nM), the MIC values are comparable at 0.125
to 0.06 g/ml (26, 31). The impact of the F98Y mutation on
(R)-RAB1 is consistent with recent observations with related
phthalazine-based DHFR inhibitors, such as BAL0030543
(Fig. 2B) (7, 9). While the three-dimensional structures with
the BAL compounds are not known, they may use a similar
binding mode such that the phthalazine group follows the path
of RAB1 form 1, while the pyrimidine moiety extending from
the phthalazine would occupy the same position as RAB1 form
2. This would present some steric strain that should exacerbate
the effect of the F98Y mutation.
While toxicology remains to be tested, predictive calcula-
tions indicate RAB1 has a higher than desirable log(P) of 5.45.
Future refinements to the structure will seek to optimize the
pharmocodynamic profile to further development of RAB1-
like candidates as viable antimicrobial therapies in our arsenal
against infectious diseases.
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